Our infection prevention
solutions reduce the risk of
infections, increase patient
safety and reduce the use of
antibiotics.
Bactiguard Holding AB (publ) published the interim report for the second quarter on Thursday July 15, 2021 at 8:00 CET.
An audiocast for investors, analysts and media was held at 11:00 CET on July 15, where CEO Cecilia Edström and CFO Gabriella Björknert Caracciolo commented on the report and answered questions.
The Zimmer Natural Nail (ZNN) Bactiguard implants are now available in Germany, Spain, and the UK, and will be made available to patients and surgeons in other select EMEA (Europe, Middle East and Africa) markets over the summer.
Hydrocyn® aqua is a non-alcoholic disinfectant solution for, for example, skin and surfaces. The active substance hypochlorous acid (HOCl) is a part of the human immune system. Hydrocyn® aqua kills:
Hydrocyn® aqua is proven effective against the SARS-CoV-2 virus that causes COVID-19 and against previous strains of coronavirus.
Watch CEO Cecilia Edström presenting Bactiguards work within infection prevention at Handelsbanken Nordic mid cap seminar.
Bactiguard’s Annual Report 2020 is now available for downloading in both Swedish and English. Find out about Bactiguard’s significant strategic advances and how we stand stronger than ever, ready to impact and drive change within infection prevention. Both in healthcare and in people’s everyday life.
Bactiguard Holding AB (publ) published the interim report for the second quarter on Thursday July 15, 2021 at 8:00 CET.
The Bactiguard technology reduces microbial adhesion to the surface of medical devices, which decreases the risk of biofilm formation leading to infection.
The BIP Foley TempSensor is an indwelling urinary catheter which combines continuous temperature monitoring with Bactiguard’s infection prevention technology.
Hydrocyn® aqua is a non-alcoholic disinfectant solution for, for example, skin and surfaces, proven effective against the new coronavirus SARS-CoV-2.
